my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
Genmab is a leading international biotechnology company focused on developing fully human antibody therapeutics for unmet medical needs. Using unique, cutting-edge antibody technology, Genmab's world class discovery and development teams have created and developed an extensive pipeline of products f more
Genmab A/S announced that GlaxoSmithKline (GSK) has agreed a settlement with Genentech Inc. and City of Hope (a California not-for-profit organization) concerning two U.S. patents that relate to recombinant antibody production for ofatumumab. GSK is Genmab’s development and commercial collaborator f more
Genmab A/S announced it had reached the second pre-clinical milestone in the collaboration with H. Lundbeck A/S, triggering a €1 million payment. Genmab has reached the second milestone in the collaboration with H. Lundbeck A/S to create and develop human antibody therapeutics for disorders of the c more
Genmab A/S announced it had reached the first pre-clinical milestone in the collaboration with H. Lundbeck A/S, triggering a €1 million payment. Genmab has reached the first milestone in the collaboration with H. Lundbeck A/S to create and develop human antibody therapeutics for disorders of the cen more
Introduction GlobalData, the industry analysis specialist, has released its new report, “Waldenström’s Macroglobulinemia Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Waldenstrom's Macroglobulinemia Ther more
Do you want to find market prospects for products and companies in the biological drugs industry? Our new report shows you biopharma revenue forecasts for 2011 to 2021. We provide original research, data and opinions to benefit your work now. What revenues will biopharmaceutical markets achieve fro more
What will this decade hold for leading anti-cancer drugs and that therapeutic market? Our new report shows you anti-cancer drug revenue forecasts for 2011 to 2021. We provide research, data and opinions to benefit your work now. What revenues will cancer treatment markets generate from 2011 to 2021 more
A A Home About Us Investors Management Board of Directors Scientific Advisory Board Technologies Antibodies Overview Intellectual Property Glossary Partnering Press Room Career Contact Maps & Directions Basel Site Maps & Directions Jena Site Press Room Recent news releases March 16, 2010: 4-Antibody more
Language: en / da Sitemap Downloads Contact Search: Core Competences Pipeline Business Development Investor Join Us About Us Cancer Biodefence Infectious Diseases Investor News Media Clippings Share Information Financials Calendar General Meetings Presentations Investor Services Contact 30 March 20 more
Skip to Content combining biology and chemistry to create diversity About » Board of Directors Kate Bingham Kate is Managing Partner at SVLS with a focus on biotechnology having joined the company in SVLS in 1991. Kate currently serves or has served on the boards of companies in the UK , US , Irelan more
Watchlist
This is where you can add this topic to your personal favourites
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
